News Releases

August 4, 2022   NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

July 6, 2022   NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

June 27, 2022   NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

June 22, 2022   Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua

June 8, 2022   NextCure to Present at the JMP Securities Life Sciences Conference

May 5, 2022   NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

May 3, 2022   NextCure to Present at the BofA Securities 2022 Healthcare Conference

April 19, 2022   NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

April 5, 2022   NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

March 3, 2022   NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results